Answers are grounded in this paper and cite their sources.
Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial. (Funded by Ionis Pharmaceuticals; ISIS 721744-CS2 ClinicalTrials.gov number, NCT04030598.).
No takes yet. Share an insight, caveat, or question.
Fijen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: